



GLAND PHARMA LIMITED

July 12, 2023

National Stock Exchange of India Limited
Surveillance Department
Exchange Plaza, 5th floor
Plot no. C-1, Block G, Bandra Kurla Complex Bandra (East), Mumbai - 400 051
Symbol: GLAND (ISIN: INE068V01023)

Dear Sir/Madam,

Sub: Clarification /Confirmation on news item appearing in “Media/Publication”

Ref. No.: NSE/CM/Surveillance/13227

This is in reference to your e-mail dated 10th July 2023 seeking clarification on news item appearing in “Media/Publication”.

In compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (SEBI (LODR) Regulations, 2015), the Company promptly intimates to the Stock Exchanges of all events and information that may have a probable bearing on the operation / performance of the Company including all price sensitive information, as and when required from time to time.

The news items appeared in the Media is correct as the Company had received approval for ANDA for Fomepizole. However, it was not falling under the criteria of the materiality to be disclosed to the stock exchanges, as the expected annual revenue is less than the materiality threshold and hence it is not categorised as UPSI. The news article has no material impact on the operations of the Company. The product approval information is also available on the USFDA website.

Please take the same on record.

Yours truly,
For Gland Pharma Limited

P Sampath Kumar
Company Secretary and Compliance Officer